{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:19:01Z","timestamp":1779175141581,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.clcc.2013.10.001","type":"journal-article","created":{"date-parts":[[2013,11,13]],"date-time":"2013-11-13T01:45:39Z","timestamp":1384307139000},"page":"62-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Pilot Clinical Trial on the Efficacy of Prophylactic Use of Vitamin K1\u2013Based Cream (Vigorskin) to\u00a0Prevent Cetuximab-Induced Skin Rash in Patients With Metastatic Colorectal Cancer"],"prefix":"10.1016","volume":"13","author":[{"given":"Francesco","family":"Pinta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agostino","family":"Ponzetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosella","family":"Spadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Fanchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Zanini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Mecca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Sonetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libero","family":"Ciuffreda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Racca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2013.10.001_bib1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(09)70330-4","article-title":"Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial","volume":"11","author":"Folprecht","year":"2004","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2013.10.001_bib2","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2013.10.001_bib3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2013.10.001_bib4","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2013.10.001_bib5","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","article-title":"EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer","volume":"26","author":"Sobrero","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2013.10.001_bib6","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1200\/JCO.2006.06.7595","article-title":"Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines","volume":"24","author":"Lenz","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2013.10.001_bib7","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as\u00a0initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2013.10.001_bib8","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdq632","article-title":"Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study","volume":"22","author":"Bokemeyer","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2013.10.001_bib9","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(11)60613-2","article-title":"Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial","volume":"377","author":"Maughan","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2013.10.001_bib10","first-page":"34","article-title":"Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae","volume":"21","author":"Wagner","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.clcc.2013.10.001_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11523-009-0114-0","article-title":"Skin toxicities associated with epidermal growth factor receptor inhibitors","volume":"4","author":"Li","year":"2009","journal-title":"Target Oncol"},{"key":"10.1016\/j.clcc.2013.10.001_bib12","first-page":"329","article-title":"Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients","volume":"18","author":"Romito","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clcc.2013.10.001_bib13","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1002\/cncr.25090","article-title":"Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life","volume":"116","author":"Joshi","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2013.10.001_bib14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2012.08.023","article-title":"Quality of life analysis in patients with\u00a0KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin","volume":"49","author":"Lang","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2013.10.001_bib15","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitors","volume":"55","author":"Agero","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clcc.2013.10.001_bib16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000229751","article-title":"Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in North Central Cancer Treatment Group study N0147","volume":"77","author":"Jatoi","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.clcc.2013.10.001_bib17","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000229752","article-title":"Risk of high-grade skin rash in cancer patients treated with cetuximab\u2014an antibody against epidermal growth factor receptor: systemic review and meta-analysis","volume":"77","author":"Su","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.clcc.2013.10.001_bib18","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3892\/or_00000319","article-title":"Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis","volume":"21","author":"Orditura","year":"2009","journal-title":"Oncol Rep"},{"key":"10.1016\/j.clcc.2013.10.001_bib19","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1200\/JCO.2011.40.9243","article-title":"Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reaction: the randomized EVEREST study","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2013.10.001_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1634\/theoncologist.2010-0298","article-title":"Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy","volume":"16","author":"Pinto","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2013.10.001_bib21","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1517\/14712598.2011.582464","article-title":"Cetuximab in the treatment of patients with colorectal cancer","volume":"11","author":"Garrett","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.clcc.2013.10.001_bib22","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2013.10.001_bib23","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cncr.23621","article-title":"Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)","volume":"113","author":"Jatoi","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2013.10.001_bib24","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2013.10.001_bib25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/11588900-000000000-00000","article-title":"Drug-induced acneiform eruption","volume":"12","author":"Du-Thanh","year":"2011","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clcc.2013.10.001_bib26","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaad.2006.06.046","article-title":"Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy","volume":"56","author":"DeWitt","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clcc.2013.10.001_bib27","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/sj.jid.5701184","article-title":"The epidermal growth factor receptor system in skin repair and inflammation","volume":"128","author":"Pastore","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.clcc.2013.10.001_bib28","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/annonc\/mdq387","article-title":"Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion","volume":"22","author":"Potthoff","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2013.10.001_bib29","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cbpa.2009.03.021","article-title":"The therapeutic potential of phosphatase inhibitors","volume":"13","author":"Vintonyak","year":"2009","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.clcc.2013.10.001_bib30","article-title":"Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin","author":"Perez-Soler","year":"2006","journal-title":"ASCO Annual Meeting Proceedings"},{"key":"10.1016\/j.clcc.2013.10.001_bib31","doi-asserted-by":"crossref","first-page":"6766","DOI":"10.1158\/1078-0432.CCR-11-0545","article-title":"The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab","volume":"17","author":"Perez-Soler","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2013.10.001_bib32","article-title":"Steroids and immunosuppressive agents potentiate the cytotoxicity of the EGFR inhibitor erlotinib in human keratinocytes whereas Vit K3 exerts a protective effect: implications for the management of skin rash","author":"Perez-Soler","year":"2007","journal-title":"ASCO Annual Meeting Proceedings"},{"key":"10.1016\/j.clcc.2013.10.001_bib33","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1468-3083.2011.04324.x","article-title":"Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis","volume":"27","author":"Tomkova","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clcc.2013.10.001_bib34","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1468-3083.2009.03446.x","article-title":"Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer","volume":"24","author":"Ocvirk","year":"2010","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clcc.2013.10.001_bib35","article-title":"Treatment of cetuximab-associated cutaneous side effects using topical application of vitamin K1 cream","author":"Ocvirk","year":"2009","journal-title":"ASCO Annual Meeting Proceedings"},{"key":"10.1016\/j.clcc.2013.10.001_bib36","article-title":"Vitamin K1 cream in the management of skin rash during anti-EGFR monoclonal antibody (mAb) treatment in patients with metastatic cancer: first analysis of an observational Italian study","author":"Pinto","year":"2011","journal-title":"Gastrointestinal Cancers Symposium"},{"key":"10.1016\/j.clcc.2013.10.001_bib37","article-title":"Analysis of the effects of vitamin K1 cream on cetuximab-induced acne-like rash","author":"Radovics","year":"2010","journal-title":"ASCO Annual Meeting Proceedings"},{"key":"10.1016\/j.clcc.2013.10.001_bib38","unstructured":"Common Terminology Criteria for Adverse Events, version 3.0. Available at: ctep.cancer.gov\/reporting\/ctc.html. Accessed: September 21,\u00a02013."},{"key":"10.1016\/j.clcc.2013.10.001_bib39","first-page":"48","article-title":"Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic\/dermatologic cooperation","volume":"7","author":"Racca","year":"2008","journal-title":"Clin Colorectal Cancer"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002813001175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002813001175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:02:36Z","timestamp":1761519756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002813001175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S1533002813001175"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2013.10.001","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pilot Clinical Trial on the Efficacy of Prophylactic Use of Vitamin K1\u2013Based Cream (Vigorskin) to\u00a0Prevent Cetuximab-Induced Skin Rash in Patients With Metastatic Colorectal Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2013.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}